

PHARMACOLOGY
BIOCHEMISTRY
AND
BEHAVIOR

VOLUME 48, 1994
SUBJECT AND AUTHOR INDEX



PERGAMON

PHARMACOLOGY BIOCHEMISTRY AND BEHAVIOR

US Editor-in-Chief

MATTHEW J. WAYNER

Division of Life Sciences, The University of Texas at San Antonio, San Antonio, TX 78249-0662

European Editor-in-Chief

SANDRA E. FILE

Psychopharmacology Research Unit, UMDS Division of Pharmacology, Guy's Hospital
P.O. Box 3448, London SE1 9QH, UK

Editorial Advisory Board

LIISA AHTEE, Helsinki, Finland
LEMBIT ALLIKMETS, Tartu, Estonia
ROBERT L. BALSTER, Richmond, VA
GIOVANNI BIGGIO, Cagliari, Italy
MIKE BRILEY, Castres, France
ALLAN C. COLLINS, Boulder, CO
DONALD V. COSCINA, Toronto, Ontario, Canada
JACQUELINE N. CRAWLEY, Bethesda, MD
ANNETTE DOMENEY, Geneva, Switzerland
ADRIAN J. DUNN, Shreveport, LA
BURR EICHELMAN, Philadelphia, PA
WILLIAM J. FREED, Washington, DC
MANUEL FREIRE-GARABEL, Santiago De Compostella, Spain
RICHARD A. GLENNON, Richmond, VA
F. G. GRAEFF, São Paulo, Brazil
M. R. C. GREENWOOD, Davis, CA
ROLAND R. GRIFFITHS, Baltimore, MD
STEPHEN G. HOLTZMAN, Atlanta, GA
AKIRA HORITA, Seattle, WA
CHRIS E. JOHANSON, Baltimore, MD
HAROLD KALANT, Toronto, Ontario, Canada
G. JEAN KANT, Washington, DC
KATHLEEN M. KANTAK, Boston, MA
GEORGE F. KOOB, La Jolla, CA

CONAN KORNETSKY, Boston, MA
J. DAVID LEANDER, Indianapolis, IN
EMINY H. Y. LEE, Taipei, Taiwan
ALLEN S. LEVINE, Minneapolis, MN
WILLIAM J. McBRIDE, Indianapolis, IN
DONALD E. McMILLAN, Little Rock, AR
JACK H. MENDELSON, Belmont, MA
FATHY S. MESSIHA, Grand Forks, ND
ROBERT D. MYERS, Greenville, NC
JUDITH A. PRATT, Glasgow, UK
JAQUELINE SAGEN, Chicago, IL
ROSARIO SAMANIN, Milan, Italy
HERMAN H. SAMSON, Winston-Salem, NC
PAUL R. SANBERG, Tampa, FL
PHIL J. SKOLNICK, Bethesda, MD
LINDA P. SPEAR, Binghamton, NY
CLARE STANFORD, London, UK
MARIE-HÉLÈNE THIÉBOT, Paris, France
DEREK VAN DER KOOT, Toronto, Ontario, Canada
JEANNE M. WEHNER, Boulder, CO
BRUNO E. WILL, Strasbourg, France
J. C. WINTER, Buffalo, NY
ALICE M. YOUNG, Detroit, MI
IAN S. ZAGON, Hershey, PA

PHARMACOLOGY BIOCHEMISTRY AND BEHAVIOR

US Editorial Office:

Matthew J. Wayner

Division of Life Sciences, The University of Texas at San Antonio, 6900 North Loop 1604 West
San Antonio, TX 78249-0662
Fax: (210) 691-4510

European Editorial Office:

Sandra E. File

Psychopharmacology Research Unit, UMDS Division of Pharmacology, Guy's Hospital
P.O. Box 3448, London SE1 9QH, UK
Fax: 44-(0)71-955-4627

Production Editor:

Alayne A. Bakken

E-mail: A.BAKKEN@ELSEVIER.COM

Publishing, Subscription, and Advertising Offices:

Elsevier Science Inc., 660 White Plains Road, Tarrytown, NY 10591-5153, USA, E-mail Address:
ESUK.USA@ELSEVIER.COM; and Elsevier Science Ltd, The Boulevard, Langford Lane, Kidlington,
Oxford OX5 1GB, England

Published Monthly

Annual Institutional Subscription Rates (1994): North, Central and South America, US\$1440.00, Rest of World
£935.00. Associated Personal Subscription Rates are available on request for those whose institutions are library
subscribers. Sterling prices exclude VAT. Non-VAT registered customers in the European Community will be
charged the appropriate VAT in addition to the price listed. Prices include postage and insurance and are subject to
change without notice.

Pharmacology Biochemistry and Behavior is an official journal of the International Behavioral Neuroscience
Society. For information about the society, please contact: Dr. Linda Spear, Department of Psychology, State
University of New York at Binghamton, Box 6000, Binghamton, NY 13902-6000, USA. Members of the Interna-
tional Behavioral Neuroscience Society may order personal subscriptions at a concessional rate; details of this rate
are available upon request.



SUBJECT INDEX

- A δ fibers, 447
 Absence epilepsy, 547, 575
 Acetic acid, 371
 Acetylcholine, 417, 613
 Acoustic startle response, 307
 ACTH, 429
 Active avoidance, 805
 Activity, 581
 Acute dependence, 397
 Adenylate cyclase, 983, 991
 Adrenal demedullation, 887
 Adrenal gland, 977
 Adrenaline, 887
 Age factors, 999
 Aging, 575
 Agonists, 241
 Alcohol, 105, 999
 Alcohol preference, 105
 α_1 -Adrenoceptor agonists/antagonists, 601
 α -Helical CRF₉₋₄₁, 497
 Alpha-helical CRH₍₉₋₄₁₎, 887
 α -Methyl-*p*-tyrosine
 Alpha-Methyl-5-HT, 315
 Alpha-methyl-para-tyrosine, 93
 Alprazolam, 69, 845
 Amnesia, 971
 AMPA antagonists, 111
 Amphetamine, 23, 63, 161, 459, 581, 681, 839, 853, 1005, 1019
 Amygdala, 307, 677
 Analgesia, 57, 87, 357, 411
 Anesthesia, 547
 Animal model(s), 403, 1025, 671
 Anorectic agents, 371
 Anorexia, 601
 Antagonism, 275
 Antagonists, 241, 1019
 Anterograde amnesia, 805
 Anticonvulsant, 765
 Antidepressant, 47, 119, 845
 Antinociception, 37, 175, 699
 Antiserum, 699
 Anxiety, 223, 281, 307, 525, 893, 959
 Anxiety model, 497
 Anxiolytic, 497
 Apomorphine, 423, 799, 839, 1053
 Ascorbic acid, 161
 Aspirin, 1047
 Assay, 813
 Ataxia, 111
 Attention, 23, 935
 Autoshaping, 1025

 BALB/C, 497
 Barbiturate, 593
 Basal ganglia, 235, 441

 BC 264, 363
 Behavior, 119
 Behavior genetics, 733
 Behavioral depression, 845
 Behavioral development, 447
 Behavioral history, 491
 Behavioral sensitization, 151, 265, 587
 Behavioral suppression, 281, 959
 Behavioral tolerance, 265
 Behavioural observations, 259
 Benzodiazepine receptor, 553, 765
 Benzodiazepine(s), 357, 69, 223, 535
 β -Adrenoceptors, 971
 β -Endorphin, 563, 699
 Beta-blocking drugs, 965
 Binding protein, 813
 Binge eating, 1025
 Biotelemetry, 703
 Blood alcohol, 105
 Blood levels, 715
 Blood pressure, 429, 899
 Body weight, 357
 Bombesin, 881
 Brain, 87
 Brain injury, 773
 Brain stimulation, 487
 Branched-chain amino acids, 101
 Bretazenil, 397
 Broiler chicks, 371
 Bromocriptine, 839, 853
 Buprenorphine, 723
 Buspirone, 315
 Butorphanol tartrate, 1025
 BW2258U89, 809

 C57BL mice, 327
 C57BL/6J, 169
 C57BL/6J, 733
 C fibers, 447
 Ca²⁺ antagonist, 613
 Cadmium, 543
 Caffeine, 217, 899
 Caffeine pharmacokinetics, 337
 Caffeine tolerance, 337
 Calcium, 37
 Calcium antagonist, 575
 Calcium currents, 77
 cAMP, 813
 Carbachol, 93
 Carbohydrate intake, 193
 Carbon monoxide (CO), 9
 Castration, 265, 515
 Catalepsy, 357, 605
 Catecholamines, 621, 773
 CCK, 275
 CCK-B receptors, 363

 Cecum, 371
 Cerebral protection, 613
 CGP 39551, 571
 Chemical adrenalectomy, 977
 Chick, 971, 1047
 Chickens, 479
 Chlormipramine, 1037
 Chlordiazepoxide, 397
 Cholecystokinin, 363, 479, 809, 1019
 Cholinergic system, 93
 Chronic, 755
 Chronic administration, 575
 Chronic exposure, 643
 Chronic treatment, 119
 Cigarettes, 539
 Cirazoline, 601
 Circadian rhythm, 709
 Circling, 681
cis-Flupenthixol, 681
 Citalopram, 315
 Clobazam, 765
 Clonazepam, 765
 Clonidine, 93
 Clozapine, 253
 CO₂, 345
 Cocaine, 151, 169, 217, 265, 327, 403, 453, 473, 487, 491, 511, 715, 733, 909, 915, 1025
 Coffee, 899
 Cognition, 235
 Color and position discrimination, 935
 Conditioned fear, 525
 Conditioned individual preference, 677
 Conditioned place preference, 459, 677
 Conditioned taste aversion(s), 601, 635
 Conditioned taste preference, 651
 Conditioning, 479, 791
 Conspecific discrimination, 677
 Context-specific, 791
 Copulation, 423
 Copulatory behavior, 1011
 Core body temperature, 703
 Core temperature, 119
 Corticosterone, 53, 977
 Cortisol, 377
 CRF, 497, 1031
 Crosstolerance, 765
 Current, 915
 Current-frequency trade-off, 557
 Cyclic AMP, 37

 D₁, 741
d-Amphetamine, 465, 787, 1053
 DBA mice, 327
 DBA/2J, 169
 DBA/2J, 733

- D-CPP-ene, 587
 D-Cycloserine, 351
 Delay-to-reinforcement, 47
 Delayed matching-to-sample, 935
 Delayed-matching-to-sample, 183
 Delayed memory loss, 971
 Δ^9 -tetrahydrocannabinol, 1011
 Dependence, 535
 Desipramine, 47, 315
 Devazepide, 275, 1019
 Development, 403
 DFP, 703
 Diazepam, 183, 535, 557, 665, 765, 787
 Diet, 57
 Differential outcomes, 183
 Differential rearing, 459
 Differential reinforcement of low response rate, 69
 Differing ages, 87
 Dimethylxanthines, 337
 Discrimination, 1041
 Diuresis, 63
 Dizocilpine, 9, 723
 DNA synthesis, 709
 DOI, 383, 1041
 DOI-HCl, 315
 DOPAC, 297, 515
 Dopamine, 9, 43, 53, 141, 235, 241, 423, 515, 521, 525, 581, 605, 621, 651, 671, 681, 741, 781, 791, 853, 915, 1005, 1011, 1031, 1053
 Dopamine agonist, 531
 Dopamine antagonists, 817
 Dopamine D₁ receptor, 465
 Dopamine D₂ receptor(s), 465, 781
 Dopamine D₃ receptor, 531
 Dopamine extracellular output, 351
 Dopamine receptor subtypes, 151
 Dopamine receptors, 465
 Dopamine transporter, 327
 Dopamine uptake inhibitor, 135
 Dopamine, reuptake, 817
 Dopamine-mediated behaviors, 351
 Dopaminergic agonists, 839
 Dorsal raphe nucleus, 1041
 Drinking, 63
 Drinking behavior, 105
 Drug abuse, 977
 Drug discrimination learning, 635
 Drug discrimination, 275, 473, 531
 Drug reward, 459
 Drug sensitization, 1005
 Duration, 253

 Ear-scratch response, 383
 ECS, 315
 Edema, 1037
 Edothelin, 1031
 EEG, 259
 8-OHDPAT, 315
 Electrical stimulation, 1041
 Electronic diary, 899
 Electrophysiology, 983, 991
 Elevated plus-maze, 689, 959
 Endogenous bovine satiety agent, 17
 Environmental enrichment, 459
 Environmentally induced oral stereotypies, 241
 Epidepride, 327
 Epilepsy, 553
 Epithelium, 709
 Estrogen, 417
 Estrous cycle, 417
 Ethanol, 31, 141, 229, 297, 543, 593, 893, 929
 Ethanol preference, 977
 Ethanol reinforced behavior, 141
 Ethological analysis, 959
 Ethyl, 999
 Excitatory amino acid(s), 9, 693
 Exercise, 563
 Exploration, 291, 839, 1053
 Extinction, 217
 Eye opening, 447

 Fatty acid composition, 1047
 Fawn-hooded rats, 105
 Fear, 307
 Feed restriction, 371
 Feeding, 63, 135, 875
 Feeding behavior, 809
 Female, 909
 Fenfluramine, 105, 875
 Fentanyl, 547
 Field experiment, 899
 Fischer-344 male rats, 411
 5,7-DHT, 315
 5-HT, 223, 875, 971
 5-HT_{1A} receptor agonists, 281
 5-HT_{1A} receptors, 959
 5-HT_{1B} receptors, 971
 5-HT₂ agonist(s), 805, 1041
 5-HT₂ antagonist, 613
 5-Hydroxytryptamine, 1041
 Fixed ratio, 253
 Fixed-interval (FI), 69, 853
 Fixed-interval schedule, 209, 491
 Fixed-ratio, 69
 Fixed-ratio schedule, 209, 511
 Flesinoxan, 959
 Fluanisone, 547
 Flumazenil, 69
 Flunitrazepam, 665
 Fluoxetine, 411
 Fluphenazine, 605
 Fluvoxamine, 845
 Focal ischemia, 77
 Food consumption, 119
 Food deprivation history, 1025
 Food intake, 17, 809
 Food reinforcement, 935
 Food restriction, 241
 Foot shocks, 307
 Forced swimming test, 43
 Forskolin, 37, 813
 Fourth ventricle, 749
 Fowls, 241
 FRL rats, 703
 Functional recovery, 773

 G-Proteins, 37
 GABA, 613, 893
 GABA_A-benzodiazepine receptor complex, 69
 GABA-receptor complex, 101
 Ganglionic blockade, 887
 Gastric ulcers, 53
 Gastrin-releasing peptide, 809
 Gastrointestinal tract, 371
 GBR 12909, 135, 327, 817
 GBR-12909, 915
 GBR 12935, 733
 Generalization, 635
 Genetic epilepsy model, 547, 575

 Genetics, 593
 Gepirone, 301
 Gerbils, 983, 991
 Glue thinner, 661
 Glutamate, 259, 587
 Glutamatergic AMPA/kainate receptors, 437
 Glutamic acid, 203
 Glutathione, 845
 Gonadal hormones, 265
 Grooming, 1031
 Growth, 709, 1047
 Growth factors, 709

 Habituation, 839
 Haloperidol, 63, 151, 161, 671
 Hamsters, 791
 Head-twitch response, 383
 Headache, 899
 Heart rate, 703, 899
 Hemiplegia, 773
 Hexamethonium, 887
 Hippocampus, 1053
 HMPAO, 553
 Hole blocking, 539
 Hormone, 977
 Hot plate, 357
 HPLC purification, 17
 HPNS, 259
 Human, 899
 Human subjects, 715
 Huntington's disease, 441
 Hydrogen peroxide, 845
 Hyperactivity, 921
 Hyperalgesia, 411, 1037
 Hypercholinergic FSL rats, 703
 Hypnorm, 547

 Ibotenic acid lesion, 127
 ICS 205930, 193
 ICSS reward, 915
 Imipramine, 47, 845
 Immobilization stress, 297
 Immune response, 53
 In vivo binding, 69
 In vivo microdialysis, 9
 Incremental repeated acquisition, 935
 Individual behavior, 839
 Individual differences, 581, 1019
 Inescapable shock, 845
 Inflammation, 1037
 Ingestive behavior, 875
 Intensification by hypoglycemia of morphine dependence, 571
 Intoxication, 229
 Intracranial self-administration, 625
 Intracranial self-stimulation, 661
 Intracranial stimulation, 1005
 Intra gastric, 651
 Intraparabrachial injection, 127
 Intravenous, 1025
 Intraventricular, 881
 Intrinsic neurons, 127
 Iomazenil, 553
 Iron deficiency, 621

 Juveniles, 909

 Kappa opiate receptors, 87
 Ketamine, 175, 755
 Ketanserin, 383
 Key pecking, 491
 Kindling, 31, 553

- L365-260, 1019
 L-365,260, 275
 Lamotrigine, 259
 Lateral hypothalamus, 127, 625
 L-DOPA, 515
 Learned helplessness, 671
 Learning, 613, 935
 Lesions, 441
 Lethality, 357
 Lever press, 265
 Life span study, 863
 Light cigarettes, 539
 Limited access paradigm, 31
 Linoleic acid, 1047
 Lipids, 377
 Lipoproteins, 377
 Lisuride, 383
 Liver enlargement, 1047
 L-NAME, 487
 Locomotion, 363, 781, 839, 921, 1019
 Locomotor activity, 111, 291, 327, 337, 383, 459, 473, 497, 593, 749
 Locomotor behavior, 1005
 Lorazepam, 69, 183
 Lordosis, 417
 Luteinizing hormone, 1011
 Lymphocyte, 999

 MA-631, 505
Macaca mulatta, 935
 Macaque, 643
 Maharishi Ayur-Ved, 505
 Malaise, 601
 Male sexual arousal, 1011
 Maltose dextrin, 193
 Maprotiline, 845
 Marihuana, 715
 MCI-225, 345
 Mecamylamine, 749
 Medial forebrain bundle, 557
 Medial hypothalamus, 625
 Medial prefrontal cortex, 671
 Memory expression, 437
 Memory, AMPA/kainate receptors in, 437
 Memory, effects of CNQX on, 437
 Mesencephalic central gray, 625
 Mesolimbic, 521
 Mesoprefrontal dopamine neurons, 297
 Metabolic rate, 119
 Metabolism, 543
 Methadone, 47, 563
 Methamphetamine, 587, 941
 Methionine-enkephalin, 699
 Methylphenidate, 773
 Methysergide, 193, 411
 Metyrapone, 977
 Mice, 37, 69, 291, 677, 909, 959, 1031
 Microdialysis, 605, 651, 671
 Microinjection(s), 141, 315
 Microsomal lipid peroxidation, 505
 Midazolam, 357, 765
 Middle cerebral artery occlusion, 77
 MK-329, 479
 MK-801, 9, 63, 161, 571, 587, 723, 935
 (+)MK-801, 755
 Monkey(s), 235, 723
 Monoamine oxidase, 845
 Monoamines, 621
 Morphine, 127, 357, 563, 625, 677, 791
 Morphine dependence, 363
 Morphine physical dependence, 571
 Motivation, 935

 Motivational withdrawal signs, 1
 Motor activity, 119, 465, 703, 899
 Mouse strains, 497
 Mouse striatum, 813
 Mouse, 23, 689, 709, 965
 Multiple schedule, 209, 491
 Muscarinic receptors, 417

 Naloxone, 363
 Naloxone-precipitated opioid withdrawal, 1
 Naloxone-precipitated withdrawal, 791
 Naltrexone, 193, 709
 Neonatal capsaicin, 447
 Neuroleptanalgesia, 547
 Neurological deficits, 77
 Neuronal calcium channels, 77
 Neuropeptide Y, 681
 Neuroprotection, 77
 Neurosteroids, 893
 Nicotine, 37, 209, 521, 749
 Nicotine discrimination, 817
 Nicotine tolerance, 209
 Nimodipine, 575
 Nitric oxide, 487, 689, 799
 Nitric oxide synthase inhibition, 689
 Nitrous oxide, 689, 699
 NMDA, 203, 291, 441
 NMDA antagonists, 111, 755
 NMDA receptor, 9
 N-methyl-D-aspartate, 587
 NNC 09-0026, 77
 Noradrenaline, 307
 Noradrenergic system, 93
 Norepinephrine, 515, 525, 773, 1011
 Novelty, 581
 NPY, 1031
 Nucleus accumbens, 141, 315, 651
 Nutritional pharmacology, 101

 Obesity, 57
 Odorant recognition, 515
 Olfactory bulb, 515
 Oligemia, 613
 1-(2-Pyrimidinyl)-piperazine, 301
 1-Methyl-4-phenyl-1,2,3,6-tetrahydro-pyridine, 235
 Ontogeny, 781
 Open field, 315
 Open-field behaviours, 441
 Operant behavior, 69, 935
 Operant responding, 1
 Opiate antagonists, 635
 Opiate receptors, 677
 Opioid(s), 47, 241, 357, 709
 Oral ingestion, 563
 Organic solvent, 661
 Organophosphates, 643
 Oscillating bar, 229
 Ovariectomy, 265
 Oxidative stress, 845
 Oxotremorine, 703
 Oxygen deficit, 613
 Oxytocin, 203, 799

 PA, 345
 Palatability, 875
 Pancreatic α -amylase, 371
 Paradoxical sleep, 93
 Paraventricular nucleus, 203
 Paraventricular nucleus of the hypothalamus, 799

 Partial agonists and antagonists, 281
 Passive avoidance, 301
 Penile erection, 203, 423, 799
 Pentobarbital, 593
 Pentylentetrazol-induced seizures, 575
 Phencyclidine, 77, 465, 941
 Physical exercise, 377
 Physical withdrawal signs, 1
 Physostigmine, 417
 Pigeons, 47, 183, 491
 Pimozide, 253, 791
 Place conditioning, 581
 Place preference, 581
 Placebo controlled, 899
 Plus-maze, 497
 Polydrug abuse, 715
 Preference test, 479
 Prefrontal cortex, 1053
 Pregnenolone, 893
 Pregnenolone sulfate, 893
 Prenatal hypoxia exposure, 863
 Primates, 259
 Proadifen, 301
 Probucol, 505
 Proconvulsant drugs, 101
 Prolactin, 429, 1011
 Propionic acid, 371
 Prostration, 749
 Protein kinase, 813
 Protein kinase C, 999
 Punished responding, 491

 Quinine, 875
 Quinpirole, 781

 Radial maze, 23
 Rapid, 755
 Rat fetus, 741
 Rat social interaction, 223
 Rat(s), 1, 87, 93, 111, 127, 135, 141, 203, 253, 259, 265, 281, 301, 307, 315, 351, 397, 453, 515, 521, 581, 651, 661, 699, 781, 787, 799, 881, 921, 941, 1019, 1025, 1041
 Receptor, 429
 Receptor binding, 111
 Receptor subtypes, 241
 Regional cerebral blood flow, 553
 Reinforcement, 581
 Reinforcement frequency, 941
 Reinstatement, 217
 Reinstatement of cocaine-taking behavior, 217
 REM sleep deprivation, 43
 Renin, 429
 Reproduction, 909
 Response duration differentiation, 941
 Response force, 511
 Restraint stress, 53
 Reticular formation, 625
 Reverse tolerance, 921
 Reward, 487, 581
 Righting reflex, 535
 Ritanserin, 193, 315, 473
 Ro 15-4513 binding, 223
 Rotation, 441
 R(+)-SCH-23390, 151
 Running wheel, 839

 Saccharin, 127, 723
 Satiation, 809
 Satiety, 479

- SCH 23390, 327, 817, 853, 741
 SCH23390, 43
 Schedule-controlled behavior, 47, 265, 397, 511
 Schedule-induced defection, 787
 Schedule-induced ptydipsia, 209
 Scopolamine, 23, 161, 183, 345, 417
 Scratching, 447
 Self-administration, 217, 453, 473, 723, 1025
 Self-stimulation, 853
 Sensitivity, 229
 Sensitization, 169, 307, 605, 791
 Serotonergic 5-HT_{1B} agonist, 965
 Serotonergic system, 665
 Serotonin, 9, 105, 429, 525, 671, 875, 1011
 Set point, 881
 7-OH-DPAT, 531
 Sexual behavior, 417
 Sexual motivation, 929
 Sexual reinforcement, 929
 Shock postponement, 491
 Short-term memory, 935
 SKF 38393, 853
 SKF-38393, 741
 Smoking, 539
 Sniffing, 135
 Social isolation, 965
 Sotalol, 971
 Spatial memory, 613
 Spatial working memory, 23
 Spike-wave discharges, 547, 575
 Spinal cord, 87
 Spinal rats, 693
 Spinal transection, 175
 Spiperone, 383, 817, 853
 Spontaneously hypertensive rat, 57
 ST-91, 307
 Startle, 453
 Stereotyped behavior, 853
 Stereotypy, 111, 169, 1053
 Stimulation, 915
 Stimulation-induced feeding, 557
 Stress, 377
 Striatum, 651, 681
 Sucrose, 141, 193, 563, 875
 Sulpiride, 43
 Sweeteners, 991
 Symptom relevant experience (SRE), 773
 Tail flick, 175, 357, 693
 Tando spirone, 805
 Taste, 983, 991
 Taste aversion, 275, 875
 Taste conditioning, 1
 Taste reactivity, 875
 Temperature gradient, 881
 Temperature regulation, 119
 Temporal response differentiation, 935
 Testosterone, 377
 Tetrahydrocannabinol, 715
 THA, 345
 Thermoregulation, 881
 Thiobarbituric acid-reactive substances, 505
 [³H]-MK 801, 351
 [³H]-SCH 23390, 351
 [³H]-spiroperidol binding studies, 351
 Time course of sensitization, 921
 Time estimation, 935
 Tobacco, 539
 Tolerance, 169, 253, 535, 587, 605, 755, 765
 Toluene, 505
 Tongue, 709
 Tracking performance, 643
 Trazodone, 845
 Treadle pressing, 491
 Tremor, 665
 2,2',2''-Tripyridine, 665
 U50,488H, 63
 U-50,488H, 87
 Ultralight cigarettes, 539
 Ultrasonic vocalisation, 301
 Uric acid, 161
 Vestibular reflexes, 535
 Vitamin E, 505
 Voltammetry, 161
 Voluntary alcohol selection, 31
 VTA, 1005
 WAG/Rij rat, 547
 Wakefulness, 899
 Water maze, 345, 613
 Well-being, 899
 Wistar rats, 575
 Wistar-Kyoto rat, 57
 Withdrawal, 453, 723
 Withdrawal syndrome, 363
 Working memory, 183
 Yawning, 203, 423, 799
 Yohimbine, 307

PHARMACOLOGY BIOCHEMISTRY & BEHAVIOR

VOLUME 48 1994

AUTHOR INDEX

- Abekawa, T., 587
Abreu, M. E., 497
Acuff, C. G., 57
Adams, S. L., 941
Advokat, C., 175, 693
Akasofu, K., 423
Akunne, H. C., 411
Allen, R. R., 935
Alling, K., 511
Alvarez Sanz, M. C., 429
Andrew, R. J., 971
Andrews, N., 223
Argiolas, A., 203, 799
Asakura, W., 43
Askanazi, J., 101
Ates, N., 547, 575
Atrens, D. M., 853
Avery, D. D., 881
- Bane, A. J., 881
Bardo, M. T., 459
Barnfield, A., 875
Barone, F. C., 77
Barrett, J. E., 491
Bartke, A., 1011
Bättig, K., 899
Beard, J. L., 621
Belzung, C., 23
Ben-Shahar, O., 1005
Bengtsson, A., 465
Beninger, 681
Beuzen, A., 23
Bhargava, H. N., 87
Bianchi, M., 1037
Bianchin, M., 437
Bidzinski, A., 315
Bielajew, C., 557
Black, M. D., 441
Blick, D. W., 644
Bondar, R. J., 193
Borlongan, C. V., 677
Bowling, S. L., 459
Bozarth, M. A., 487
Bratton, G. R., 543
Bresink, I., 111
Bronson, M. E., 397
Brown, G. C., 643
Buffalo, E. A., 935
Burke, T. F., 69
Burkey, R. T., 543
Burnham, W. M., 31
Bushnik, T., 557
- Carmona, G. N., 723
Carney, J. M., 169, 733
Carrillo, P., 447
Carroll, M. E., 723, 1025
- Caton, P. W., 689
Cazala, 625
Chakravarti, A. K., 53
Charrier, D., 281
Chau, A., 755
Chen, C.-J., 909
Chen, M. J., 773
Chen, Q., 621
Cleary, J., 47
Clemente, J., 805
Coen, K. M., 817
Coenen, A. M. L., 547
Cole, J. C., 959
Coleman, G. J., 563
Compton, A. D., 253
Connor, J., 621
Conti, L. H., 497
Cooper, S. J., 135
Coper, H., 863
Corrigall, W. A., 817
Costello, D. G., 497
Cottrell, G., 31
Covasa, M., 479
Crossman, A. R., 441
Cullen, W. K., 301
- Dai, H., 921
Dall'Olio, R., 351
Damaj, M. I., 37
Dandiya, P. C., 845
Dangoumau, L., 281
Danysz, W., 111
Dark, K. A., 403
Darlington, C. L., 535
Darmani, N. A., 383
David, V., 625
Davies, A., 959
Davies, A. M., 875
Davies, B. T., 601
de Saint Hilaire-Kafi, Z., 93
Debray, M., 965
DeLeon, I., 787
DePetrillo, P. B., 999
Derrien, M., 363
Diana, G., 291
Dixon, M., 1041
Dluzen, D. E., 515
Dohanich, G. P., 417
Dougherty, T., 193
Dudek, B. C., 593
Duncan, W. C., Jr., 119
- Egawa, M., 345
Eguchi, J., 345
Eina, H., 921
Ejantkar, A., 703
Elliott, P. J., 441
- Elmaliah, S., 371
Emmett-Oglesby, M. W., 473
Engel, J. A., 977
Erb, S. M., 581
Erickson, R. P., 983
Erwin, V. G., 327
Espinoza, M., 791
Essmann, U., 111
Ettenberg, A., 929, 1005
- Fahlke, C., 977
Falk, J. L., 209, 337
Feeney, D. M., 773
Fendt, M., 307
Feuerstein, G., 77
File, S. E., 223
Flood, J. F., 1031
Flores, R., 791
Forbes, J. M., 479
Frances, H., 965
Fukushima, T., 553
Fukuzako, H., 715
Furuse, M., 1047
- Gagnon, M. J., 699
Gaillard, J.-M., 93
Gandolfi, O., 351
Gatlin, L. A., 983
Gerdes, C. F., 383
Gher, J., 1011
Ghorpade, A., 175, 693
Gibbs, J., 809
Gillam, M. P., 935
Gordon, C. J., 119, 703
Grady, D. R., 105
Grover, C. A., 543
Guan, X., 515
Gyorda, A. M., 491
- Halsey, M. J., 259
Hamon, M., 281
Hanna, A. N., 505
Hansen, S., 977
Hara, S., 699
Haraguchi, M., 141
Hård, E., 977
Hardwick, W. C., 941
Hatipoğlu, I., 571
Hay, M., 563
Hayes, A. G., 441
Heim, C., 613
Heiman, S. A., 983
Higgins, G. A., 1
Higgins, G. A., 1019
Hiramatsu, M., 9
Hisada, K., 553
Hodge, C. W., 141
- Hoebel, B. G., 651
Höfer, I., 899
Hsu, K.-S., 665
Hunt, G. E., 853
- Ida, Y., 297
Inoue, M., 547
Islam, A. K., 193
Israel, Y., 229
Izquierdo, I., 437
- Jackson, D. M., 465, 853
Jaehkel, M., 839
Jakobsen, P., 77
Jänicke, B., 863
Jaskiw, G. E., 1053
Jessa, M., 315
Jibiki, I., 553
Jin, C.-B., 57
Johansson, C., 465
Jones, B. C., 327, 621
- Kalant, H., 755
Kameyama, T., 9
Katner, J. S., 525
Kauffman, E. M., 505
Kelley, A. E., 915
Khanna, J. M., 755
Kirkham, T. C., 809
Kline, A. E., 773
Koch, J. E., 193
Koch, M., 307
Kostal, L., 241
Kostowski, W., 315
Kouri, E., 715
Kovera, C. A., 47
Koyama, T., 587
Koyuncuoğlu, H., 571
Kozłowski, L. T., 539
Kramer, G., 671
Krug, D., 161
Kunimoto, K., 429
Kunko, P. M., 161
Kurokawa, K., 553
- Lac, S. T., 1025
Lau, C. E., 209, 337
Lê, A. D., 229
Leban, J., 809
Leblanc, J., 887
LeSage, M., 787
Levy, A. D., 429
Li, Q., 429
Lin-Shiau, S.-Y., 665
Lindgren, L.-M., 465
Linseman, M. A., 31
Lipska, B. K., 1053

- Losee M. L., 991
 Lukas, S. E., 715

 Maclean, C. J., 259
 Makhay, M., 511, 787
 Maldonado, R., 363
 Maldonado-Irizarry, C. S., 915
 Manner, T., 101
 Mansbach, R. S., 453
 Manzo, J., 447
 Mark, G. P., 651
 Markou, A., 453
 Martin, B. R., 37
 Martin, L. A., 497
 Martinez-Gomez, M., 447
 Mastrangelo, D., 93
 Matsuda, H., 553
 Matsuguchi, N., 297
 Matsumoto, K., 43
 Matwyshyn, G. A., 87
 McClure, G. Y. H., 941
 McDermid, J., 809
 McEldowney, S. S., 423
 McElroy, J. F., 531
 McLachlan, C. D., 563
 McLaughlin, P. J., 709
 McMahon, L. R., 601
 McMillan, D. E., 941
 Medina, J. H., 437
 Meil, W., 605
 Melchoir, C. L., 893
 Meldrum, B. S., 259
 Melis, M. R., 203, 799
 Melton, P. M., 275
 Menard, C. S., 417
 Mendelson, J. H., 715
 Merali, Z., 681
 Meyer, M. E., 781
 Miles, C., 875
 Miller, L. G., 69
 Mock, O. B., 383
 Moeller, M., 671
 Moerschbaeher, J. M., 69
 Mokler, D. J., 1041
 Monier, C., 965
 Moore, E., 681
 Morato, G. S., 755
 Morien, A., 601
 Morley, J. E., 1031
 Morris, M., 487
 Morse, A. C., 539
 Moufid-Bellancourt, S., 127
 Mueller, K., 161
 Munirathinam, G., 813
 Murai, A., 1047
 Muraki, A., 587
 Murphy, L. L., 1011
 Murphy, M. R., 643
 Museo, E., 521
 Mustafa, S., 921

 Nabeshima, T., 9
 Nagy, J., 17
 Nation, J. R., 543
 Nazar, M., 315
 Nencini, P., 63
 Newman, H. A. I., 505

 Oehler, J., 839
 Ohmori, T., 587
 Ohta, H., 43
 Okumura, J.-I., 1047
 Olster, D. H., 929
 Overmier, J. B., 47, 183
 Overstreet, D. H., 703

 Pacheco, P., 447
 Pal, S. N., 845
 Palejko, W., 315
 Panerai, A. E., 1037
 Parker, L. A., 581, 875
 Patrick, G. A., 453
 Paule, M. G., 935
 Pearce, P. C., 259
 Peeke, H. V. S., 403
 Peltier, R. L., 473
 Petersen, A. J., 101
 Petrov, E. S., 741
 Petty, F., 671
 Pillitteri, J. L., 539
 Pinchasov, Y., 371
 Plaznik, A., 315
 Poling, A., 511, 787
 Porter, J. H., 253
 Potter, T. J., 781
 Price, W. J., 77
 Pudiak, C. M., 487
 Puech, A. J., 281
 Puri, S., 53

 Quartermain, D., 805
 Quillfeldt, J. A., 437
 Quock, R. M., 689, 699

 Racotta, I. S., 887
 Rada, P. V., 651
 Ramsey-Williams, V. A., 765
 Rattan, A. K., 357
 Ray, A., 53
 Reddy, P. L., 87
 Reid, K., 57
 Rezvani, A. H., 105
 Rezvani, A. H., 703
 Richard, D., 887
 Riley, A. L., 275, 635
 Rimondini, R., 351
 Rittenhouse, P. A., 429
 Ritzmann, R. F., 893
 Robinson, S. R., 741
 Rockhold, R. W., 57
 Rodefer, J. S., 723
 Rodgers, R. J., 959
 Roeltgen, D. P., 235
 Roques, B. P., 363
 Rosenberg, H. C., 765
 Roullet, P., 23
 Rowan, M. J., 301
 Rusche, W. P., 525

 Sacerdote, P., 1037
 Sachs, B. D., 423
 Sagratella, S., 291
 Sajdyk, T. J., 525
 Salamy, A., 403

 Salas, M., 447
 Salfi, M., 403
 Samson, H. H., 141
 Saponjic, R. M., 161
 Sarica, O., 571
 Savage, L. M., 183
 Savory, C. J., 241
 Schaal, D. W., 47
 Schenk, S., 217, 473
 Scherrer, J., 1031
 Schiffman, S. S., 983, 991
 Schmitz, P. K., 437
 Schneider, J. S., 235
 Schnitzler, H.-U., 307
 Schnur, P., 791
 Schumacher, H. E., 839
 Scott, M. P., 929
 See, R. E., 605
 Sellers, E. M., 1, 1019
 Sen, P., 53
 Sgouraki, E., 377
 Shah, G., 755
 Shah, S. N., 403
 Sharma, H. M., 505
 Sheardown, M. J., 77
 Shekhar, A., 525
 Shemer, A., 805
 Shergill, H. K., 259
 Shibuya, T., 699
 Shiro, I., 297
 Shoaib, M., 749
 Sholar, M., 715
 Sieklucka, M., 613
 Sills, T. L., 1019
 Simon, J. R., 525
 Skeie, B., 101
 Smith, G. P., 809
 Smith, P. F., 535
 Smith, S. E., 651
 Smotherman, W. P., 741
 Smurthwaite, S. T., 635
 Soliman, K. F. A., 411
 Sontag, K.-H., 613
 Spear, D. J., 209
 Specker, S. M., 1025
 Sribanditmongkol, P., 357
 Stagner, W. C., 983
 Stalikas, A., 377
 Stambaugh, L., 1041
 Stancampiano, R., 203, 799
 Stanchfield, M. A., 183
 Steen, P. A., 101
 Stefanski, R., 315
 Steger, R. W., 1011
 Stellar, J. R., 915
 Stephenson, R. M., 971
 Stolerman, I. P., 749
 Stump, B. S., 881
 Suggs, M. S., 983, 991
 Sullivan, R. M., 921
 Sun, Z.-Q., 235
 Szechtman, H., 921

 Tatham, T. A., 491
 Tejedor-Real, P., 363
 Tella, S. R., 151
 Thiébot, M.-H., 281

 Thomas, W. H., 473
 Thomasson, R., 977
 Thompson, T., 47
 Tindley, G., 259
 Tobe, A., 345
 Tolliver, B. K., 169, 733
 Tolliver, G. A., 141
 Tomkins, D. M., 1019
 Tousman, S. A., 689
 Towns, L. C., 383
 Tritto, T., 593
 Tso-Olivas, D. Y., 773
 Tsopanakis, A., 377
 Tsopanakis, C., 377
 Tsuji, S., 553
 Tsujimaru, S., 297

 Underwood, K. A., 593

 Vaccarino, F. J., 1019
 Valadez, A., 217
 Valeri, P., 63
 Valverde, O., 363
 van de Kar, L. D., 429
 van der Hoek, G. A., 135
 van der Staay, F. J., 575
 van Haaren, F., 265
 van Hartesveldt, C., 781
 van Luijtelaa, E. L. J. M., 575
 Vandenberg, J. G., 909
 Varlinskaya, E. I., 741
 Veeranna, 87
 Velley, L., 127
 Vossen, J. M. H., 547

 Walsh, C. A., 809
 Walz, R., 437
 Ward, E. M., 259
 Watanabe, H., 43
 Watanabe, S., 677
 Weathersby, D. W., JR., 643
 Weinberger, D. R., 1053
 Welch, S. P., 37
 Wellman, P. J., 601
 Wenger, G. R., 941
 White, M. F., 497
 Wiley, J. L., 253
 Wilke, R., 111
 Wise, R. A., 521
 Wolfe, E., 693
 Womer, D. E., 327
 Worley, C. M., 217
 Wu, Y., 709, 765

 Yamaguchi, N., 553
 Yavich, L., 661
 Yoburn, B. C., 813
 Yokoyama, S., 9
 Yracheta, J. M., 429
 Yuasa, T., 345

 Zagon, I. S., 709
 Zanatta, M. S., 437
 Zhang, T., 57
 Zvartau, E., 661